Literature DB >> 7924061

[18p-syndrome with bilateral pyramidal tract signs, dystonia of the lower extremities and concentric visual field defect].

S Kakinuma1, F Sasabe, K Negoro, H Nogaki, M Morimatsu.   

Abstract

A case, diagnosed as 18p-syndrome by typical clinical appearance and by chromosomal analysis, presented with multiple nervous system defects consisting of bilateral pyramidal tract signs, weakness and focal dystonia of the lower extremities, and concentric visual field defect. Chromosomal analysis revealed karyotype 46, X, dic (Y;18) (p11;p11), inv(9) (p11q13), and the points of chromosomal breakages were thought to be in the short arm of chromosome 18 and in the short arm of Y chromosome. 18p-syndrome is caused by a chromosomal deletion, and presents with a wide variety of clinical appearances. Many cases have been reported since the original descriptions by de Grouchy in 1963, though with few mentions of neurological deficits other than mental retardation. Furthermore, there have been no reports of pyramidal tract signs, weakness and focal dystonia of the lower extremities, or visual field defect, without recognizable anatomical abnormalities. Our case of 18p-syndrome is quite rare because of multiple nervous system abnormalities mentioned above, not accompanied by malformations of the central nervous system.

Entities:  

Mesh:

Year:  1994        PMID: 7924061

Source DB:  PubMed          Journal:  Rinsho Shinkeigaku        ISSN: 0009-918X


  3 in total

1.  Dystonia in a patient with deletion of 18p.

Authors:  F Tezzon; T Zanoni; M G Passarin; G Ferrari
Journal:  Ital J Neurol Sci       Date:  1998-04

2.  Spectrum of Movement Disorders in 18p Deletion Syndrome.

Authors:  David Crosiers; Bettina Blaumeiser; Gert Van Goethem
Journal:  Mov Disord Clin Pract       Date:  2018-12-06

3.  Search for a founder mutation in idiopathic focal dystonia from Northern Germany.

Authors:  C Klein; L J Ozelius; J Hagenah; X O Breakefield; N J Risch; P Vieregge
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.